What should I tell a patient who has an elevated hemoglobin of 17.5 g/dL and hematocrit of 51.3%?

Elevated Hemoglobin and Hematocrit: Clinical Evaluation and Management

Your patient requires immediate evaluation to determine the cause of their elevated hemoglobin (17.5 g/dL) and hematocrit (51.3%), as these values exceed normal ranges and warrant investigation for polycythemia vera, secondary erythrocytosis, or other underlying conditions.

Initial Assessment and Differential Diagnosis

Determine if Values Meet Diagnostic Thresholds

• For men: Hemoglobin ≥18.5 g/dL or hematocrit ≥49% raises concern for polycythemia vera (PV), though your patient's values are elevated but below this threshold 1, 2
• For women: Hemoglobin ≥16.5 g/dL or hematocrit ≥48% meets major criteria for PV 1, 2
• Your patient's values (Hgb 17.5, Hct 51.3) are significantly elevated regardless of sex and require workup 3

Clinical Context Matters

Assess for secondary causes before pursuing myeloproliferative neoplasm workup:

• Hypoxic conditions: Chronic lung disease, sleep apnea, high altitude residence, smoking, or cyanotic heart disease can cause compensatory erythrocytosis 4, 5
• Dehydration: Can falsely elevate hematocrit; ensure patient is euvolemic before interpretation 4, 5
• Testosterone therapy: Common cause of polycythemia with hematocrit often exceeding 54% in treated patients 6, 7
• Renal pathology: Renal cell carcinoma or renal artery stenosis can cause inappropriate erythropoietin production 8

Recommended Diagnostic Workup

First-Line Testing

Order serum erythropoietin (EPO) level as the initial diagnostic test:

• Low EPO (below reference range): Highly suggestive of PV with >90% specificity, though sensitivity is only ~70% 8
• Normal EPO: Does not exclude PV; proceed with bone marrow evaluation if clinical suspicion remains 8
• Elevated EPO: Suggests secondary erythrocytosis; investigate hypoxic causes 8

Second-Line Testing Based on EPO Results

If EPO is low or normal with persistent concern:

• JAK2 V617F mutation testing: Present in >90% of PV cases; functionally similar JAK2 exon 12 mutations found in JAK2 V617F-negative cases 1, 2
• Bone marrow biopsy: Shows hypercellularity with trilineage growth (panmyelosis) in PV; required for definitive diagnosis 1, 2
• Complete blood count with differential: Assess for leukocytosis, thrombocytosis suggesting myeloproliferative neoplasm 8

Cardiovascular Risk Considerations

Thrombotic Risk with Elevated Hemoglobin

Elevated hemoglobin significantly increases cardiovascular events:

• Hemoglobin ≥17.5 g/dL in men associated with hazard ratio of 3.52 for myocardial infarction and 2.36 for ischemic stroke compared to normal ranges 9
• Hemoglobin ≥17 g/dL independently associated with increased risk for new cardiac events (HR 1.22) 10
• Even hemoglobin >16.0 g/dL in women shows increased arterial thrombosis risk 9

When to Consider Therapeutic Phlebotomy

Phlebotomy is indicated only in specific circumstances:

• In cyanotic congenital heart disease: Only when hemoglobin >20 g/dL AND hematocrit >65% WITH symptoms of hyperviscosity (headache, fatigue, poor concentration) in absence of dehydration 4, 5
• Before noncardiac surgery: Reasonable when hematocrit >65% 5
• NOT indicated: For hemoglobin <20 g/dL or hematocrit <65% without hyperviscosity symptoms 5
• Avoid repeated routine phlebotomies: Risk of iron depletion, decreased oxygen-carrying capacity, and stroke 4

Immediate Patient Communication

What to Tell Your Patient Now

Explain the following key points:

1. Their values are elevated and require investigation to determine if this represents a primary bone marrow disorder (polycythemia vera) versus a secondary/reactive process 1, 8

2. Blood work is needed including erythropoietin level, JAK2 mutation testing, and complete metabolic panel 8, 2

3. Cardiovascular risk is increased with these hemoglobin levels, particularly for heart attack and stroke 9, 10

4. Avoid dehydration as this worsens blood viscosity and thrombotic risk 4, 5

5. Review medications and exposures: Specifically ask about testosterone therapy, which commonly causes this finding and requires dose adjustment or discontinuation if hematocrit >54% 6, 7

6. Phlebotomy is NOT routinely recommended at these levels unless specific criteria are met 4, 5

Common Pitfalls to Avoid

• Do not assume this is benign: Even modest elevations increase cardiovascular risk 9, 10
• Do not perform therapeutic phlebotomy prematurely: Can cause iron deficiency and paradoxically increase stroke risk 4
• Do not miss iron deficiency: Can mask true hemoglobin elevation in PV; formal diagnosis may require iron replacement first 3
• Do not overlook testosterone therapy: Present in 44% of repeat blood donors with persistently elevated hemoglobin ≥180 g/dL 7
• Do not delay workup: Early diagnosis of PV before development of cirrhosis or thrombotic complications improves outcomes 11